<DOC>
	<DOC>NCT02231450</DOC>
	<brief_summary>The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of Lu AE58054 following a single oral dose of Lu AE58054</brief_summary>
	<brief_title>Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Men and women aged between 40 and 65 years (inclusive) with a body mass index between 19 and 32 kg/m2 (inclusive). Group 1: Patients with mild hepatic impairment (ChildPugh's Criteria A, score 56) Group 2: Patients with moderate hepatic impairment (ChildPugh's Criteria B, score 79) Group 3: Healthy subjects with normal hepatic function Other predefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>AE58054</keyword>
	<keyword>Hepatic impairment</keyword>
</DOC>